Komori
Other Disclosures4579RaQualia Pharma Inc.Medicines

Notice Regarding the Marketing Authorization of the Acid Secretion Inhibitor Tegoprazan in Brazil

Eurofarma, the partner to which we licensed the acid secretion inhibitor tegoprazan, has obtained marketing authorization in Brazil. The product is named “TREV,” and has been approved for 3 indications.

Worth reading
79Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

tegoprazanTREV
Applicable field (uses covered by this announcement)
Erosive gastroesophageal reflux diseaseNon-erosive gastroesophageal reflux diseaseGastric ulcers
Contract Date2022 (technology transfer agreement between HK inno.N Corporation and Eurofarma)
What the company reported numerically
Usage history

Domestic sales in South Korea (outpatient prescription results) exceeded KRW 1 trillion cumulatively in April 2026. Tegoprazan products are sold in 22 countries.

Relationship between the counterparty and the company
RaQualia Pharma Inc.4579
Relationship with the Company

RaQualia Pharma licensed tegoprazan to HK inno.N Corporation. HK inno.N Corporation and Eurofarma entered into a technology transfer agreement for tegoprazan in 2022. Under its licensing agreement with HK inno.N Corporation, the company holds the right to receive a portion of the revenue that HK inno.N Corporation receives from its partner.

CounterpartyHK inno.N CorporationEurofarma Laboratórios S.A.Brazil’s National Health Surveillance Agency (ANVISA)

HK inno.N Corporation: Headquartered in Osong, South Korea. Eurofarma Laboratórios S.A.: Headquartered in São Paulo, Brazil, and a major pharmaceutical company. ANVISA: Brazil’s Health Regulatory Agency.

Award/certification name

Marketing authorization from ANVISA; GMP certification from ANVISA for tegoprazan drug substance

Awarding / certifying body

Brazil’s National Health Surveillance Agency (ANVISA)

Location (as indicated in this announcement)

HK inno.N Corporation’s Daejeo plant (location details: Not disclosed)

Impact on Business Performance

The company will receive a milestone payment and recognize it as business revenue in the fourth quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the year disclosed on 13 February 2026.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

HK inno.N Corporation website (Korean)

Announced details
ItemDetails
Names of Products / Services Coveredtegoprazan, TREV
CounterpartyHK inno.N Corporation, Eurofarma Laboratórios S.A., Brazil’s National Health Surveillance Agency (ANVISA)
Counterparty overviewHK inno.N Corporation: Headquartered in Osong, South Korea. Eurofarma Laboratórios S.A.: Headquartered in São Paulo, Brazil, and a major pharmaceutical company. ANVISA: Brazil’s Health Regulatory Agency.
Relationship with the CompanyRaQualia Pharma licensed tegoprazan to HK inno.N Corporation. HK inno.N Corporation and Eurofarma entered into a technology transfer agreement for tegoprazan in 2022. Under its licensing agreement with HK inno.N Corporation, the company holds the right to receive a portion of the revenue that HK inno.N Corporation receives from its partner.
Contract Date2022 (technology transfer agreement between HK inno.N Corporation and Eurofarma)
Applicable areaErosive gastroesophageal reflux disease, Non-erosive gastroesophageal reflux disease, Gastric ulcers
Award/certification nameMarketing authorization from ANVISA; GMP certification from ANVISA for tegoprazan drug substance
Awarding / certifying bodyBrazil’s National Health Surveillance Agency (ANVISA)
LocationHK inno.N Corporation’s Daejeo plant (location details: Not disclosed)
Usage historyDomestic sales in South Korea (outpatient prescription results) exceeded KRW 1 trillion cumulatively in April 2026. Tegoprazan products are sold in 22 countries.
Impact on Business PerformanceThe company will receive a milestone payment and recognize it as business revenue in the fourth quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the year disclosed on 13 February 2026.
SourceHK inno.N Corporation website (Korean)
Items this document does not state (6)
Contract ValueOffering priceLaunch dateRegistration number and expiry dateLocation scaleQuantitative Effects

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the marketing authorization from ANVISA is expected to enable entry into the Brazilian market and advance business expansion in Latin America. The company will receive a milestone payment and recognize it as business revenue in the fourth quarter of the fiscal year ending December 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.